Indicators in the LPA model included baseline Scale of Prodromal Symptoms (SOPS), Calgary Depression Scale for Schizophrenia (CDSS), and neurocognitive performance as measured by multiple instruments, including category instances (CAT).
A multivariate model including baseline features and pexelizumab treatment found anterior MI location and pre-PCI TIMI flow to be significant independent predictors infarct size (p=0.001), whereas pexelizumab was not (p=0.29).
The model included baseline lactate as its strongest component, as well as age over 75 years, acute coronary syndrome as the etiology of CS, previous history of myocardial infarction or coronary artery bypass surgery, altered mental status at presentation, renal function, and left ventricular ejection fraction below 40% at baseline.
To quantitatively measure the effect of antibody fluctuation on NPC risk, the second model included baseline measurement as constant variable, and the differences between each repeated test and baseline measurement as time-varying variables.
In a study that followed children from 3 to 6 years, a model including baseline BMI and PA predicted only 65% of the variance in follow-up BMI [41], compared with 93% in our study.
Groups were compared using an ANCOVA model including baseline values as covariates.
For the analysis by sex, the model included baseline eGFR and center as covariates.
We then re-tested any significant differences using this multivariate model including baseline scores.
The model included baseline, treatment, study, tiredness subgroup, and treatment-by-tiredness subgroup interaction.
The fixed effects specified in the model included baseline values (age, sex, vintage and comorbidity) and study week (0 12 weeks).
